![Enterome announces sustained positive clinical outcomes with EO2401](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
31 May 2023
Enterome announces sustained positive clinical outcomes with EO2401
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform, today announces...